Powered by: Motilal Oswal
2025-10-31 06:03:05 pm | Source: Axis Securities Ltd
Pick of the Week : Buy Krishna Institute Of Medical Sciencs Ltd For the Target Rs.792 by Axis Securities Ltd
Pick of the Week : Buy Krishna Institute Of Medical Sciencs Ltd For the Target Rs.792 by Axis Securities Ltd

Investment Rationale

A. Expansion & Cluster-Based Growth Model Driving Scale

* KIMS has built a dominant presence in South India, with offering more than 40 multi-specialties services (~5,000 beds operational) following a hub-and-spoke cluster model. The company’s asset-light approach—favoring brownfield expansions, lease-based additions, and selective acquisitions— continues to deliver capital-efficient growth. Its focus on operational excellence, regional depth, and affordability differentiates it from peers in the tertiary care segment.

B. Accelerated Expansion Nearing Completion

* Over the past two to three years, KIMS has undertaken an aggressive and well-calibrated expansion program, combining organic, inorganic, and asset-light initiatives across both existing and new regions. The company is in the final phase of this investment cycle, with plans to add ~1,800 beds over the next 12 months, largely in H2FY26E. This expansion includes brownfield additions in Telangana and Andhra Pradesh and greenfield/leased facilities in new geographies such as Karnataka, Maharashtra, and Odisha.

C. Regional Leadership and Scalable Model

* KIMS commands strong brand equity in Telangana and Andhra Pradesh, with growing visibility in Karnataka and Maharashtra.

* Its replicable cluster strategy anchored by regional hubs and peripheral spokes offers operational synergies, improved doctor utilization, and steady occupancy ramp-up in new hospitals

Outlook & Valuation

* KIMS is well-positioned for sustained growth, supported by strategic expansions, a favorable case mix, and rising ARPOB. Although occupancy has seen a temporary dip, the company’s emphasis on high-value specialties, operational efficiencies, and regional expansion is expected to underpin long-term profitability.

* KIMS Currently trading at 33x/25x EV/EBITDA for FY26E/FY27E

 

 

For More Axis Securities Disclaimer https://simplehai.axisdirect.in/disclaimer-home

SEBI Registration number is INZ000161633

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here